Cargando…

CD66b as a prognostic and predictive biomarker in patients with non-small cell lung cancer treated with checkpoint blockade immunotherapy

Detalles Bibliográficos
Autores principales:	Jain, Swati, Ma, Kevin, Morris, Luc G. T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007870/ https://www.ncbi.nlm.nih.gov/pubmed/36915573 http://dx.doi.org/10.21037/tcr-22-2880

Ejemplares similares

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy
por: Aversa, Ilenia, et al.
Publicado: (2020)

Update on checkpoint blockade therapy for lymphoma
por: Kline, Justin, et al.
Publicado: (2015)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

The Puzzle of Predicting Response to Immune Checkpoint Blockade
por: Onyshchenko, Mykola
Publicado: (2018)

Efficacy and safety of immune checkpoint blockade for brain metastases
por: Harary, Maya, et al.
Publicado: (2019)

Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade
por: Barragan, Isabel
Publicado: (2020)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
por: Sun, Shangqin, et al.
Publicado: (2021)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
por: Leclerc, Marine, et al.
Publicado: (2019)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade
por: Oliver, Javier, et al.
Publicado: (2023)

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
por: Naidoo, Jarushka, et al.
Publicado: (2017)

Immune checkpoint blockade and biomarkers of clinical response in non–small cell lung cancer
por: Hallqvist, Andreas, et al.
Publicado: (2020)

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
por: Yoo, Seong-Keun, et al.
Publicado: (2022)

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
por: Lau, Asa P. Y., et al.
Publicado: (2023)

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
por: Xu, Yufei, et al.
Publicado: (2022)

FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
por: Symeonides, Stefan N., et al.
Publicado: (2017)

Checkpoint immunotherapy for NK/T cell lymphoma—Time for a showdown?
por: Chan, Jason Yongsheng, et al.
Publicado: (2021)

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
por: Lee, Ju Yeon, et al.
Publicado: (2016)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2018)

Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy
por: Wang, Dongdong, et al.
Publicado: (2023)

Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
por: Solinas, Cinzia, et al.
Publicado: (2021)

Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
por: Guo, Ya, et al.
Publicado: (2022)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Prognostic value of biomarkers in primary small cell carcinoma of the esophagus
por: Wang, Yan, et al.
Publicado: (2020)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
por: Gubin, Matthew M., et al.
Publicado: (2014)

A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
por: Guram, Kripa, et al.
Publicado: (2019)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Duan, Xiaopin, et al.
Publicado: (2019)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
por: Lin, Xiaoning, et al.
Publicado: (2021)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
por: Yang, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dh8sd3e4inbssd0e150ja0diac